Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update (DNG00042)

Sanofi

Status: Completed

Conditions: Dengue Virus Infection

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT04170140

DNG00042

U1111-1233-9599 (Other Identifier)

Details and patient eligibility

About

The primary objective of the study is to evaluate the effectiveness of additional risk minimization measures material by assessing the knowledge and understanding of healthcare professionals regarding the key safety messages provided in the material.

The secondary objective of the study is to evaluate if healthcare professionals know Dengvaxia product information, namely, age indication and contraindications.

Full description

The study is a cross-sectional Survey. Study data are collected through a questionnaire.

Enrollment: 300 patients

Sex: All

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthcare professionals who are current or past prescribers of Dengvaxia

Exclusion criteria

• Healthcare professionals who have never prescribed Dengvaxia
• Healthcare professionals who may have a conflict of interest with the survey (i.e. Healthcare professionals employed by regulatory bodies, pharmaceutical industries)
• Healthcare professionales who have participated in testing the questionnaire for comprehensibility, consistency and the appropriateness of medical terms

The above information is not intended to contain all considerations relevant to participation in the survey.

Trial design

300 participants in 1 patient group

Prescribers of Dengvaxia

Description:

Healthcare professionals who are current or past prescribers of Dengvaxia

Treatment:

Other: No intervention